Researchers at the University of Montreal and St. Justine Hospital have identified a new receptor called GPR91 that can cure a number of eye diseases in diabetics, premature babies and the elderly by activating growth of blood vessels. The study is the first of its kind to show how ganglion cells that need oxygen to nourish produce blood vessels to feed themselves. Doctors have expressed their concern about the uncontrolled growth of blood vessels that can eventually cut the retina off the back of the eye causing vision loss. They are, now, working on various aspects of the study such as the receptor’s ability to drive the formation of blood networks and blocking GPR91 to stop tumor growth.

Paradigm Medical Industries plans to introduce the Glaid-PERG electrophysiology instrument for the early detection of Glaucoma at the American Society for Cataract Refractive Surgeons (ASCRS) Conference in Chicago, Illinois, in April. The company’s CEO Raymond Cannefax said, “All research and studies indicate the Glaid-PERG diagnostic device is the earliest means of detecting cellular losses attributed to glaucoma and other ocular ailments.” The early diagnosis of Glaucoma, which causes the most cases of vision loss, will help reduce these cases.